Muscular Dystrophy News6d
Phase 1/2 trial of exon 44 skipping therapy for DMD cleared in UK
Entrada plans to initiate clinical testing of ENTR-601-44 in Duchenne MD patients amenable to exon 44 skipping later this year.
Entrada gets UK MHRA authorisation to begin Phase I/II trial of DMD treatment
Entrada Therapeutics has secured authorisation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to ...
marketinference6d
Entrada Therapeutics Initiates Phase 1/2 Study for Duchenne Muscular Dystrophy
The Elevate-44-201 study is a global, two-part, randomized, double-blind placebo-controlled phase 1/2 study evaluating the ...